Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 648 full-time employees. The company went IPO on 2021-07-23. The firm is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
Dr. Wenbin Jiang is the Chairman of the Board of Cytek Biosciences Inc, joining the firm since 2021.
What is the price performance of CTKB stock?
The current price of CTKB is $4.57, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Cytek Biosciences Inc?
Cytek Biosciences Inc belongs to Life Sciences Tools & Services industry and the sector is Health Care
What is Cytek Biosciences Inc market cap?
Cytek Biosciences Inc's current market cap is $587.4M
Is Cytek Biosciences Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Cytek Biosciences Inc, including 3 strong buy, 4 buy, 4 hold, 0 sell, and 3 strong sell